GLUE logo

GLUE
Monte Rosa Therapeutics Inc

1,419
Mkt Cap
$1.53B
Volume
653,721.00
52W High
$25.77
52W Low
$3.51
PE Ratio
-30.47
GLUE Fundamentals
Price
$18.80
Prev Close
$19.15
Open
$19.04
50D MA
$17.69
Beta
1.48
Avg. Volume
926,315.14
EPS (Annual)
-$0.465
P/B
5.29
Rev/Employee
$824,480.00
$964.64
Loading...
Loading...
News
all
press releases
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday
Monte Rosa Therapeutics (NASDAQ:GLUE) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-monte-rosa-therapeutics-inc-stock...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 15,837,633 shares...
MarketBeat·2d ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating an...
MarketBeat·10d ago
News Placeholder
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 22.2%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling...
MarketBeat·15d ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $103,398.05 in Stock
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average...
MarketBeat·21d ago
News Placeholder
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold...
MarketBeat·21d ago
News Placeholder
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...
MarketBeat·1mo ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen cut shares of Monte Rosa Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) released its earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·1mo ago
News Placeholder
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00
Guggenheim lowered their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a research note on Wednesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest GLUE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.